

Amendments to the claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claims 1-21. (Cancelled).

22. (Currently amended): A sustained release pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable carrier therefor, ~~which~~ wherein said composition is a unit dose composition adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione of at least 50 ng/mL over a period of 12 hours.

23. (Currently amended): A sustained release pharmaceutical composition according to claim 22, ~~which~~ wherein said composition is adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione within the range of 50 to 200 ng/mL over a period of 12 hours.

24. (Currently amended): A sustained release pharmaceutical composition according to claim 22, ~~which~~ wherein said composition is adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in the range of 50 to 120 ng/mL over a period of 12 hours.

25. (Currently amended): A sustained release pharmaceutical composition according to claim 22, ~~which~~ wherein said which composition is adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in the range of 50 to 100 ng/mL over a period of 12 hours.

26. (Currently amended): A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, ~~which~~ wherein said method comprises

the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 22.

27. (Currently amended): A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, ~~which~~ wherein said method comprises the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 23.

28. (Currently amended): A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, ~~which~~ wherein said method comprises the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 24.

29. (Currently amended): A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, ~~which~~ wherein said method comprises the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 25.

30. (Currently amended): A sustained release pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable carrier therefor, ~~which~~ wherein said composition is a unit dose composition adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione of at least 50 ng/mL over a period of 16 hours.

31. (Currently amended): A sustained release pharmaceutical composition according to claim 30, ~~which~~ wherein said composition is adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione within the range of 50 to 200 ng/mL over a period of 16 hours.

32. (Currently amended): A sustained release pharmaceutical composition according to claim 30, ~~which~~ wherein said composition is adapted to provide a plasma

concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in the range of 50 to 120 ng/mL over a period of 16 hours.

33. (Currently amended): A sustained release pharmaceutical composition according to claim 30, ~~which~~ wherein said composition is adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in the range of 50 to 100 ng/mL over a period of 16 hours.

34. (Currently amended): A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, ~~which~~ wherein said method comprises the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 30.

35. (Currently amended): A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, ~~which~~ wherein said method comprises the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 31.

36. (Currently amended): A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, ~~which~~ wherein said method comprises the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 32.

37. (Currently amended): A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, ~~which~~ wherein said method comprises the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 33.